Contineum Therapeutics

CTNM · NASDAQ

$8.46+$1.02 (+13.71%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $7.44

CTNM analyst rating

BuyConsensus of 4 analysts over the last 12 months. 50% rate it a buy.

Strong buy0
Buy2
Hold2
Underperform0
Sell0

12-month price target · 9 analysts

Average $22.44 (+165.2% upside)

Low: $17.17
Now: $8.46
High: $29.40

Upgrades and downgrades

The latest rating actions, newest first

CTNM analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Jones Trading	Oct 15, 2026	Maintains	Buy	$24.00 → $30.00	53%
Baird	Oct 14, 2026	Downgrade	Outperform → Neutral	$19.00 → $14.00	49%
Morgan Stanley	Sep 28, 2026	Maintains	Equal-Weight	$18.00 → $17.00	49%
Jones Trading	Sep 15, 2026	Maintains	Buy	$26.00 → $24.00	53%
Baird	Sep 15, 2026	Maintains	Outperform	$20.00 → $19.00	49%
RBC Capital	Jul 31, 2026	Maintains	Outperform	$22.00 → $23.00	44%
Morgan Stanley	May 14, 2026	Maintains	Equal-Weight	$14.00 → $16.00	49%
Baird	Mar 6, 2026	Maintains	Outperform	$14.00 → $20.00	49%
Morgan Stanley	Jan 8, 2026	Downgrade	Overweight → Equal-Weight	$23.00 → $14.00	49%
Baird	Nov 24, 2025	Maintains	Outperform	$16.00 → $14.00	49%

The case for and against

Updated Oct 31, 2025

Bull case

Contineum Therapeutics Inc. is positioned favorably due to its robust financial foundation, highlighted by cash and equivalents of $190.7 million, which is expected to adequately fund operations through 2027, allowing for the advancement of its promising drug candidates PIPE-791 and PIPE-307. The company's progress in the early stages of clinical trials demonstrates good pharmacokinetics and safety, building confidence as it looks forward to entering Phase II trials in 2025 with backing from an experienced partner. Additionally, the substantial unmet need in multiple sclerosis (MS) indicates that any positive outcomes from the company's candidates could capture significant market interest, enhancing the potential for future growth.

Bear case

Contineum Therapeutics Inc faces significant risks that contribute to a negative outlook for its stock, primarily driven by the potential for developmental setbacks related to its drug candidates, PIPE-791 and PIPE-307. These include the possibility of unexpected safety signals, failure to secure regulatory approvals, and challenges in the commercialization of PIPE-791, particularly given its existing partnership with Johnson & Johnson. Additionally, the company operates without any revenue streams, which raises concerns about its ability to fund ongoing research and development amidst intense competition and operational challenges.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.